Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer
6y agoen
From the article
Niraparib treatment resulted in a 38% reduction in the risk of disease progression or death in the study population compared to placebo.
Continue reading on GSKYou might also wanna read
Keenova eyes Xiaflex as first drug for plantar fibromatosis
pharmaphorum·1h ago
GSK ends dementia alliance with Alector after setbacks
pharmaphorum·2h ago
NICE aims to cut funding for Amgen lung cancer drug Lumykras
pharmaphorum·3h ago
Is pure play pharma's new pharmakon?
pharmaphorum·3h ago
Roy Jakobs to join GSK Board as Non-Executive Director
GSK·3h ago
AZ, Ionis hit by unexpected Wainua trial failure
pharmaphorum·4h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.